Comparative Pharmacology
Head-to-head clinical analysis: PROCHLORPERAZINE versus THIORIDAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCHLORPERAZINE versus THIORIDAZINE HYDROCHLORIDE.
PROCHLORPERAZINE vs THIORIDAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prochlorperazine is a phenothiazine antipsychotic that acts as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) and at high doses in the mesolimbic system. It also has anticholinergic and antiemetic effects.
Thioridazine is a typical antipsychotic of the phenothiazine class. It blocks postsynaptic dopamine D2 receptors in the mesolimbic system, and also has significant anticholinergic and alpha-adrenergic blocking activity. It exhibits a high affinity for D2, 5-HT2A, and alpha1-adrenergic receptors.
5-10 mg IM/IV every 3-4 hours as needed; or 5-10 mg PO 3-4 times daily; or 25 mg PR twice daily. Maximum IM/IV: 40 mg/day; PO: 40 mg/day.
Adults: Initial 50-100 mg orally three times daily, gradually increasing to maximum 800 mg/day in divided doses. Usual maintenance: 200-800 mg/day.
None Documented
None Documented
Clinical Note
moderateProchlorperazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone propionate."
Clinical Note
moderateProchlorperazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Prochlorperazine."
Clinical Note
moderateProchlorperazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate."
Clinical Note
moderateTerminal elimination half-life: 23-25 hours, with prolonged elimination in hepatic impairment.
24-36 hours for the parent drug; extended in hepatic impairment and elderly; steady-state reached in 4-7 days.
Renal: 70-80% (as metabolites), Fecal: 20-30% (unchanged and metabolites), Biliary: 10-15% of dose excreted in bile.
Primarily hepatic metabolism with <1% excreted unchanged in urine; metabolites are excreted renally (approximately 30% of dose as metabolites) and fecally (approximately 20-30% via bile).
Category A/B
Category A/B
Typical Antipsychotic / Antiemetic
Typical Antipsychotic
Prochlorperazine + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine."